Answer
Quizartinib and its active metabolite AC886 competitively bind with high affinity to FLT3’s ATP-binding pocket, inhibiting kinase activity and receptor autophosphorylation, thereby inhibiting downstream FLT3 signalling and blocking FLT3-ITD-dependent cell proliferation.
Sources for this answer
- Vanflyta 17.7 mg film-coated tabletDaiichi Sankyo UK Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 4Document updated
Sources checked